| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
22066 |
| Drug |
Axicabtagene ciloleucel |
| Brand |
Yescarta® |
| Indication |
For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. |
| Rapid review commissioned |
27/09/2022 |
| Rapid review completed |
10/11/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axicabtagene ciloleucel compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
30/11/2022 |
| Pre-submission consultation with Applicant |
21/03/2023 |
| Full submission received from Applicant |
06/09/2023 |
| Preliminary review sent to Applicant |
01/03/2024 |
